E
ProPhase Labs, Inc.
PRPH
$0.416
$0.00852.09%
E
Sell
8/21/2024Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to E+ from D on 8/21/2024 due to a significant decline in the efficiency index, total return index and growth index. Total revenue declined 31.92% from $3.63M to $2.47M.
ProPhase Labs, Inc. (PRPH) was downgraded to E+ from D on 8/21/2024 due to a significant decline in the efficiency index, total return index and growth index. Total revenue declined 31.92% from $3.63M to $2.47M.
D
Sell
9/12/2023Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 9/12/2023 due to a decline in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 9/12/2023 due to a decline in the total return index and volatility index.
D
Sell
8/14/2023Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C on 8/14/2023 due to a significant decline in the valuation index, solvency index and efficiency index. Net income declined 725.45% from $550 to -$3.44M, and debt to equity increased from 0.17 to 0.19.
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C on 8/14/2023 due to a significant decline in the valuation index, solvency index and efficiency index. Net income declined 725.45% from $550 to -$3.44M, and debt to equity increased from 0.17 to 0.19.
C
Hold
3/30/2023Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C from C+ on 3/30/2023 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.0577 to -$0.1506, EBIT declined 360.62% from $1.95M to -$5.09M, and operating cash flow declined 69.19% from $2.63M to $811.
ProPhase Labs, Inc. (PRPH) was downgraded to C from C+ on 3/30/2023 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.0577 to -$0.1506, EBIT declined 360.62% from $1.95M to -$5.09M, and operating cash flow declined 69.19% from $2.63M to $811.
C
Hold
11/25/2022Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C+ from B- on 11/25/2022 due to a noticeable decline in the total return index and solvency index.
ProPhase Labs, Inc. (PRPH) was downgraded to C+ from B- on 11/25/2022 due to a noticeable decline in the total return index and solvency index.
B
Buy
11/11/2022Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 11/11/2022 due to an increase in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 11/11/2022 due to an increase in the total return index and volatility index.
C
Hold
9/15/2022Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C+ from B- on 9/15/2022 due to a major decline in the growth index. Operating cash flow declined 76.24% from $20.29M to $4.82M, earnings per share declined from $0.6791 to $0.3967, and total revenue declined 38.79% from $47.53M to $29.09M.
ProPhase Labs, Inc. (PRPH) was downgraded to C+ from B- on 9/15/2022 due to a major decline in the growth index. Operating cash flow declined 76.24% from $20.29M to $4.82M, earnings per share declined from $0.6791 to $0.3967, and total revenue declined 38.79% from $47.53M to $29.09M.
B
Buy
5/19/2022Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 5/19/2022 due to a major increase in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 5/19/2022 due to a major increase in the total return index and volatility index.
C
Hold
5/16/2022Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C+ from C on 5/16/2022 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 536.56% from -$4.65M to $20.29M, earnings per share increased from $0.408 to $0.6791, and EBIT increased 18.05% from $13.68M to $16.15M.
ProPhase Labs, Inc. (PRPH) was upgraded to C+ from C on 5/16/2022 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 536.56% from -$4.65M to $20.29M, earnings per share increased from $0.408 to $0.6791, and EBIT increased 18.05% from $13.68M to $16.15M.
C
Hold
4/28/2022Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 4/28/2022 due to an increase in the total return index, valuation index and volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 4/28/2022 due to an increase in the total return index, valuation index and volatility index.
C
Hold
4/18/2022Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C- from D on 4/18/2022 due to a significant increase in the efficiency index, growth index and solvency index. EBIT increased 475.02% from -$3.65M to $13.68M, total revenue increased 376.74% from $9.47M to $45.16M, and net income increased 366.19% from -$3.98M to $10.59M.
ProPhase Labs, Inc. (PRPH) was upgraded to C- from D on 4/18/2022 due to a significant increase in the efficiency index, growth index and solvency index. EBIT increased 475.02% from -$3.65M to $13.68M, total revenue increased 376.74% from $9.47M to $45.16M, and net income increased 366.19% from -$3.98M to $10.59M.
D
Sell
12/1/2021Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 12/1/2021 due to a decline in the total return index.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 12/1/2021 due to a decline in the total return index.
D
Sell
11/16/2021Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D- on 11/16/2021 due to an increase in the valuation index.
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D- on 11/16/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 11/8/2021 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.06 to -$0.0921, EBIT declined 218.76% from $1.22M to -$1.45M, and total revenue declined 40.13% from $15.27M to $9.14M.
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 11/8/2021 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $0.06 to -$0.0921, EBIT declined 218.76% from $1.22M to -$1.45M, and total revenue declined 40.13% from $15.27M to $9.14M.
D
Sell
9/28/2020Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 9/28/2020 due to a decline in the valuation index.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 9/28/2020 due to a decline in the valuation index.
D
Sell
8/20/2020Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D on 8/20/2020 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 1,434.04% from $285 to $4.37M, earnings per share increased from -$0.0698 to $0.006, and EBIT increased 107.27% from -$812 to $59.
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D on 8/20/2020 due to a significant increase in the growth index, volatility index and total return index. Operating cash flow increased 1,434.04% from $285 to $4.37M, earnings per share increased from -$0.0698 to $0.006, and EBIT increased 107.27% from -$812 to $59.
D
Sell
7/24/2020Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 7/24/2020 due to an increase in the volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 7/24/2020 due to an increase in the volatility index.
D
Sell
7/9/2020Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 7/9/2020 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 73.23% from -$467 to -$809, and total capital declined 5.34% from $11.23M to $10.63M.
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 7/9/2020 due to a significant decline in the efficiency index, total return index and volatility index. Net income declined 73.23% from -$467 to -$809, and total capital declined 5.34% from $11.23M to $10.63M.
D
Sell
8/13/2019Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 8/13/2019 due to a large decline in the volatility index and total return index.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 8/13/2019 due to a large decline in the volatility index and total return index.
D
Sell
6/26/2019Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C- on 6/26/2019 due to a large decline in the growth index, volatility index and total return index. EBIT declined 157.14% from -$406 to -$1.04M, earnings per share declined from -$0.0408 to -$0.09, and total revenue declined 43.37% from $4.09M to $2.32M.
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C- on 6/26/2019 due to a large decline in the growth index, volatility index and total return index. EBIT declined 157.14% from -$406 to -$1.04M, earnings per share declined from -$0.0408 to -$0.09, and total revenue declined 43.37% from $4.09M to $2.32M.
C
Hold
4/16/2019Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 4/16/2019 due to a large decline in the total return index and solvency index.
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 4/16/2019 due to a large decline in the total return index and solvency index.
C
Hold
4/1/2019Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 4/1/2019 due to a major increase in the growth index, efficiency index and volatility index. Total revenue increased 67.81% from $2.44M to $4.09M, earnings per share increased from -$0.0939 to -$0.0408, and net income increased 55.82% from -$1.06M to -$467.
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 4/1/2019 due to a major increase in the growth index, efficiency index and volatility index. Total revenue increased 67.81% from $2.44M to $4.09M, earnings per share increased from -$0.0939 to -$0.0408, and net income increased 55.82% from -$1.06M to -$467.
C
Hold
12/24/2018Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C- from D+ on 12/24/2018 due to a noticeable increase in the total return index, solvency index and efficiency index. The quick ratio increased from 7.4 to 11.63.
ProPhase Labs, Inc. (PRPH) was upgraded to C- from D+ on 12/24/2018 due to a noticeable increase in the total return index, solvency index and efficiency index. The quick ratio increased from 7.4 to 11.63.
D
Sell
8/24/2018Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C on 8/24/2018 due to a substantial decline in the efficiency index, total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C on 8/24/2018 due to a substantial decline in the efficiency index, total return index and volatility index.
C
Hold
8/21/2018Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 8/21/2018 due to a substantial increase in the efficiency index.
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 8/21/2018 due to a substantial increase in the efficiency index.
C
Hold
6/21/2018Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 6/21/2018 due to a major decline in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 6/21/2018 due to a major decline in the total return index and volatility index.
C
Hold
5/23/2018Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C from B on 5/23/2018 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 84.36% from $275 to $43, earnings per share declined from $0.0224 to $0.0038, and total revenue declined 17.92% from $4.15M to $3.41M.
ProPhase Labs, Inc. (PRPH) was downgraded to C from B on 5/23/2018 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 84.36% from $275 to $43, earnings per share declined from $0.0224 to $0.0038, and total revenue declined 17.92% from $4.15M to $3.41M.
B
Buy
3/16/2018Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to B from B- on 3/16/2018 due to an increase in the total return index.
ProPhase Labs, Inc. (PRPH) was upgraded to B from B- on 3/16/2018 due to an increase in the total return index.
B
Buy
2/21/2018Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C on 2/21/2018 due to an increase in the volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C on 2/21/2018 due to an increase in the volatility index.
C
Hold
1/25/2018Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C from B- on 01/25/2018.
ProPhase Labs, Inc. (PRPH) was downgraded to C from B- on 01/25/2018.
B
Buy
11/24/2017Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 11/24/2017 due to an increase in the growth index, total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to B- from C+ on 11/24/2017 due to an increase in the growth index, total return index and volatility index.
C
Hold
11/14/2017Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C+ from C on 11/14/2017 due to a major increase in the growth index, total return index and efficiency index. Operating cash flow increased 87.89% from -$3.67M to -$445, net income increased 66.29% from -$2.31M to -$777, and earnings per share increased from -$0.1399 to -$0.05.
ProPhase Labs, Inc. (PRPH) was upgraded to C+ from C on 11/14/2017 due to a major increase in the growth index, total return index and efficiency index. Operating cash flow increased 87.89% from -$3.67M to -$445, net income increased 66.29% from -$2.31M to -$777, and earnings per share increased from -$0.1399 to -$0.05.
C
Hold
6/19/2017Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 6/19/2017 due to an increase in the volatility index and total return index.
ProPhase Labs, Inc. (PRPH) was upgraded to C from C- on 6/19/2017 due to an increase in the volatility index and total return index.
C
Hold
6/2/2017Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 6/2/2017 due to a noticeable decline in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 6/2/2017 due to a noticeable decline in the total return index and volatility index.
C
Hold
5/18/2017Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to C from D on 5/18/2017 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 7,904.02% from -$572 to $44.64M, and total capital increased 579.95% from $7.45M to $50.67M.
ProPhase Labs, Inc. (PRPH) was upgraded to C from D on 5/18/2017 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 7,904.02% from -$572 to $44.64M, and total capital increased 579.95% from $7.45M to $50.67M.
D
Sell
8/16/2016Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 8/16/2016 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.08 to -$0.066, and EBIT increased 16.36% from -$1.28M to -$1.07M.
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 8/16/2016 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.08 to -$0.066, and EBIT increased 16.36% from -$1.28M to -$1.07M.
D
Sell
8/3/2016Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 8/3/2016 due to a decline in the valuation index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 8/3/2016 due to a decline in the valuation index and volatility index.
D
Sell
7/18/2016Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 7/18/2016 due to an increase in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was upgraded to D from D- on 7/18/2016 due to an increase in the total return index and volatility index.
D
Sell
5/20/2016Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 5/20/2016 due to a noticeable decline in the solvency index, growth index and efficiency index. Total revenue declined 34.22% from $8.16M to $5.37M, debt to equity increased from 0.17 to 0.2, and total capital declined 12.91% from $10.3M to $8.97M.
ProPhase Labs, Inc. (PRPH) was downgraded to D- from D on 5/20/2016 due to a noticeable decline in the solvency index, growth index and efficiency index. Total revenue declined 34.22% from $8.16M to $5.37M, debt to equity increased from 0.17 to 0.2, and total capital declined 12.91% from $10.3M to $8.97M.
D
Sell
3/11/2016Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the total return index and volatility index.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the total return index and volatility index.
D
Sell
11/13/2015Upgraded
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D on 11/13/2015 due to a noticeable increase in the growth index, total return index and efficiency index. Operating cash flow increased 129.32% from -$1.4M to -$3.22M, total revenue increased 100.37% from $2.19M to $4.39M, and total capital increased 20.03% from $8.36M to $10.04M.
ProPhase Labs, Inc. (PRPH) was upgraded to D+ from D on 11/13/2015 due to a noticeable increase in the growth index, total return index and efficiency index. Operating cash flow increased 129.32% from -$1.4M to -$3.22M, total revenue increased 100.37% from $2.19M to $4.39M, and total capital increased 20.03% from $8.36M to $10.04M.
D
Sell
11/17/2014Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 11/17/2014 due to a large decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.63 to 1.25, and total capital declined 22.56% from $13.61M to $10.54M.
ProPhase Labs, Inc. (PRPH) was downgraded to D from D+ on 11/17/2014 due to a large decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.63 to 1.25, and total capital declined 22.56% from $13.61M to $10.54M.
D
Sell
8/13/2014Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C- on 8/13/2014 due to a significant decline in the volatility index and total return index.
ProPhase Labs, Inc. (PRPH) was downgraded to D+ from C- on 8/13/2014 due to a significant decline in the volatility index and total return index.
C
Hold
5/13/2014Downgrade
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 5/13/2014 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 234.45% from $598 to -$804, earnings per share declined from $0.0376 to -$0.05, and EBIT declined 231.26% from $611 to -$802.
ProPhase Labs, Inc. (PRPH) was downgraded to C- from C on 5/13/2014 due to a noticeable decline in the growth index, total return index and efficiency index. Net income declined 234.45% from $598 to -$804, earnings per share declined from $0.0376 to -$0.05, and EBIT declined 231.26% from $611 to -$802.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
